A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Trial Details

NCT ID

NCT05552222

Phase

PHASE3

Sponsor

Janssen Research & Development, LLC

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

Teclistamab
Daratumumab
Lenalidomide
Dexamethasone
Talquetamab

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Clovis, California, United States|36.82523,-119.70292
Irvine, California, United States|33.66946,-117.82311
Farmington, Connecticut, United States|41.71982,-72.83204
Newark, Delaware, United States|39.68372,-75.74966

Key Eligibility Criteria

Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to …
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →